{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T16:28:36Z","timestamp":1747672116277,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> Alternative administration methods are emerging as a key area of research to improve clinical efficacy of antibiotics and address concerns regarding multi-drug resistance. Extended intermittent infusions or continuous infusions of antibiotics exhibiting time-dependent kill characteristics may be favourable in critically ill septic patients, but more evidence is needed to determine best practice. <jats:italic>Objective<\/jats:italic> To find out whether any common practice exists for intravenous antibiotic administration in critical care units across UK NHS Trusts, and identify factors influencing the adoption of extended or continuous infusions. <jats:italic>Setting<\/jats:italic> UK hospitals. <jats:italic>Method<\/jats:italic> UK critical care pharmacists were invited to participate in a survey on behalf of all 240 critical care units\u00a0via a UK Clinical Pharmacy Association message board. The survey focused on administration practices for 22 antibacterial agents. <jats:italic>Main outcome measure<\/jats:italic> Antibiotic administration method. <jats:italic>Results<\/jats:italic> Responses were received covering 64 units, a response\u00a0rate of 26.2%. Common, but not uniform administration methods were apparent for 17\/22 antibiotics. Four antibiotics (piperacillin\/tazobactam, doripenem, meropenem and vancomycin) were more likely to be administered as continuous or extended-intermittent infusions. Choice of administration method was especially influenced by altered pk\/pd properties in sepsis or severe burns patients, or by the presence of organisms requiring high\u00a0minimal inhibitory concentrations. <jats:italic>Conclusion<\/jats:italic> Unlicensed alternative practices of antibiotic administration are widespread but only weak evidence exists of any patient benefit, such as reduced length of stay\u00a0in critical care, and none showing improvement in mortality. Further research is needed to determine whether extended infusion methods offer clinically meaningful advantages over shorter licenced administration methods in patients\u00a0in critical care units.<\/jats:p>","DOI":"10.1007\/s11096-019-00938-9","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T06:03:11Z","timestamp":1573711391000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A survey of antibiotic administration practices involving patients with sepsis in UK critical care units"],"prefix":"10.1007","volume":"42","author":[{"given":"Gregory J.","family":"Barton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles W.","family":"Morecroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2834-1566","authenticated-orcid":false,"given":"Neil C.","family":"Henney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"938_CR1","first-page":"Cd008481","volume":"3","author":"J Shiu","year":"2013","unstructured":"Shiu J, Wang E, Tejani AM, Wasdell M. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev. 2013;3:Cd008481.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"938_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681\u201391.","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"938_CR3","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"JL Vincent","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323\u20139.","journal-title":"JAMA"},{"issue":"2","key":"938_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","volume":"39","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165\u2013228.","journal-title":"Intensive Care Med"},{"issue":"3","key":"938_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304\u201377.","journal-title":"Intensive Care Med"},{"issue":"2","key":"938_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/cid\/cis856","volume":"56","author":"JM Dulhunty","year":"2013","unstructured":"Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56(2):236\u201344.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"938_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","volume":"192","author":"JM Dulhunty","year":"2015","unstructured":"Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298\u2013305.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"938_CR8","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/jac\/dkv165","volume":"70","author":"A Tabah","year":"2015","unstructured":"Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, et al. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother. 2015;70(9):2671\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"938_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2710.2006.00762.x","volume":"31","author":"P Llopis-Salvia","year":"2006","unstructured":"Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther. 2006;31(5):447\u201354.","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"938_CR10","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","volume":"45","author":"M Wysocki","year":"2001","unstructured":"Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45(9):2460\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"938_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507\u201314.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"938_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","volume":"47","author":"JJ Hao","year":"2016","unstructured":"Hao JJ, Chen H, Zhou JX. Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47(1):28\u201335.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"938_CR13","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1097\/CCM.0b013e318180fe62","volume":"36","author":"JA Roberts","year":"2008","unstructured":"Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance\u2013what\u2019s dosing got to do with it? Crit Care Med. 2008;36(8):2433\u201340.","journal-title":"Crit Care Med"},{"issue":"12","key":"938_CR14","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1128\/AAC.00867-13","volume":"57","author":"TW Felton","year":"2013","unstructured":"Felton TW, Goodwin J, O\u2019Connor L, Sharp A, Gregson L, Livermore J, et al. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57(12):5811\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"938_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1055\/s-0034-1398490","volume":"36","author":"MH Abdul-Aziz","year":"2015","unstructured":"Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA. Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med. 2015;36(1):136\u201353.","journal-title":"Semin Respir Crit Care Med"},{"key":"938_CR16","unstructured":"EMA. Questions and answers on tazocin and associated names (piperacillin and tazobactam, 2\/0.25\u00a0g and 4\/0.5\u00a0g powder for solution for infusion) EMEA\/H\/A-30\/001149. 2011."},{"issue":"4","key":"938_CR17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/MCC.0b013e3283021b3a","volume":"14","author":"JA Roberts","year":"2008","unstructured":"Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care. 2008;14(4):390\u20136.","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"938_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/2110-5820-2-37","volume":"2","author":"MH Abdul-Aziz","year":"2012","unstructured":"Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012;2(1):37.","journal-title":"Ann Intensive Care"},{"issue":"3","key":"938_CR19","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/cc11405","volume":"16","author":"I Chytra","year":"2012","unstructured":"Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care (London, England). 2012;16(3):R113.","journal-title":"Crit Care (London, England)."},{"issue":"2","key":"938_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CCM.0000000000002836","volume":"46","author":"NJ Rhodes","year":"2018","unstructured":"Rhodes NJ, Liu J, O\u2019Donnell JN, Dulhunty JM, Abdul-Aziz MH, Berko PY, et al. Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis. Crit Care Med. 2018;46(2):236\u201343.","journal-title":"Crit Care Med"},{"issue":"2","key":"938_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1751143714564816","volume":"16","author":"S Shah","year":"2015","unstructured":"Shah S, Barton G, Fischer A. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc. 2015;16(2):147\u201353.","journal-title":"J Intensive Care Soc"},{"issue":"3","key":"938_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jac\/44.3.319","volume":"44","author":"MJ Weinbren","year":"1999","unstructured":"Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother. 1999;44(3):319\u201327.","journal-title":"J Antimicrob Chemother"},{"key":"938_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2253-11-3","volume":"11","author":"JA Roberts","year":"2011","unstructured":"Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, et al. Antibiotic dosing in the \u2018at risk\u2019 critically ill patient: linking pathophysiology with pharmacokinetics\/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol. 2011;11:3.","journal-title":"BMC Anesthesiol"},{"key":"938_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13054-015-0750-y","volume":"19","author":"AA Udy","year":"2015","unstructured":"Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care (London, England). 2015;19:28.","journal-title":"Crit Care (London, England)."},{"issue":"9","key":"938_CR25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00134-014-3403-8","volume":"40","author":"JJ De Waele","year":"2014","unstructured":"De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, et al. Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med. 2014;40(9):1340\u201351.","journal-title":"Intensive Care Med"},{"issue":"1","key":"938_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1055\/s-0034-1396907","volume":"36","author":"K McCarthy","year":"2015","unstructured":"McCarthy K. Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy. Semin Respir Crit Care Med. 2015;36(1):44\u201355.","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"938_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1128\/AAC.38.5.931","volume":"38","author":"JW Mouton","year":"1994","unstructured":"Mouton JW, den Hollander JG. Killing of pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38(5):931\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"938_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/510590","volume":"44","author":"TP Lodise Jr","year":"2007","unstructured":"Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357\u201363.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"938_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1592\/phco.22.7.471.33665","volume":"22","author":"EM Grant","year":"2002","unstructured":"Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002;22(4):471\u201383.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"938_CR30","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072\u201383.","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00938-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-019-00938-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00938-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:14:41Z","timestamp":1605226481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-019-00938-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1007\/s11096-019-00938-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"25 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Barton GJ is employed by St Helens and Knowsley Teaching Hospitals NHS Trust as a clinical pharmacist. Morecroft CW and Henney NC declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}